Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Simmerafil - Chinese Academy of Sciences

Next Previous
Drug Profile

Simmerafil - Chinese Academy of Sciences

Alternative Names: TPN-171-H

Latest Information Update: 10 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shandong Fontacea Pharmaceutical
  • Developer Chinese Academy of Sciences; Shanghai Institute of Materia Medica; Vigonvita Life Sciences
  • Class Amides; Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Pyrimidines; Small molecules; Urologics
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Erectile dysfunction
  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 12 Apr 2024 Vigonvita Life Sciences initiates enrolment in a phase III trial for Erectile dysfunction in China (PO) (NCT06301854)
  • 01 Mar 2024 Vigonvita Life Sciences plans a phase III trial for Erectile dysfunction (In adults, In the elderly) in China (NCT06301854)
  • 11 Nov 2023 Efficacy and adverse events data from phase II trial in Pulmonary arterial hypertension presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top